The phosphoinositide 3-kinase pathway and therapy resistance in cancer
about
Combinatorial Control of mRNA Fates by RNA-Binding Proteins and Non-Coding RNAsGenetic alterations in hepatocellular carcinoma: An updatePI-103 and Quercetin Attenuate PI3K-AKT Signaling Pathway in T- Cell Lymphoma Exposed to Hydrogen PeroxideTargeting PI3K in cancer: impact on tumor cells, their protective stroma, angiogenesis and immunotherapyA phase I trial of mFOLFOX6 combined with the oral PI3K inhibitor BKM120 in patients with advanced refractory solid tumors.BKM120 induces apoptosis and inhibits tumor growth in medulloblastomaEffect of API-1 and FR180204 on cell proliferation and apoptosis in human DLD-1 and LoVo colorectal cancer cells.Expression quantitative trait loci for PI3K/AKT pathway.AKT1 and AKT2 isoforms play distinct roles during breast cancer progression through the regulation of specific downstream proteins.Phosphatidyl inositol-3 kinase (PIK3CA) E545K mutation confers cisplatin resistance and a migratory phenotype in cervical cancer cells.Genomic profiling is predictive of response to cisplatin treatment but not to PI3K inhibition in bladder cancer patient-derived xenografts.Current and future molecular diagnostics in non-small-cell lung cancer.Phosphoinositide 3-Kinase-Dependent Signalling Pathways in Cutaneous Squamous Cell Carcinomas.Upregulation of AKT3 Confers Resistance to the AKT Inhibitor MK2206 in Breast Cancer.Novel roles for class II Phosphoinositide 3-Kinase C2β in signalling pathways involved in prostate cancer cell invasion.Blockage of glutaminolysis enhances the sensitivity of ovarian cancer cells to PI3K/mTOR inhibition involvement of STAT3 signaling.Class (I) Phosphoinositide 3-Kinases in the Tumor Microenvironment.An overview of quinoline as a privileged scaffold in cancer drug discovery.Simultaneous Targeting of Bladder Tumor Growth, Survival, and Epithelial-to-Mesenchymal Transition with a Novel Therapeutic Combination of Acetazolamide (AZ) and Sulforaphane (SFN).Combined Inhibition of Cyclin-Dependent Kinases (Dinaciclib) and AKT (MK-2206) Blocks Pancreatic Tumor Growth and Metastases in Patient-Derived Xenograft Models.Expression and clinical significance of Nectin-4 in hepatocellular carcinomaThe PI3K Pathway in Human Disease.QSKL protects against myocardial apoptosis on heart failure via PI3K/Akt-p53 signaling pathway.Regulation of Serine-Threonine Kinase Akt Activation by NAD+-Dependent Deacetylase SIRT7.Insulin receptor substrate 4 (IRS4) is a constitutive active oncogenic driver collaborating with HER2 and causing therapeutic resistance.Quercetin Attenuates Cell Survival, Inflammation, and Angiogenesis via Modulation of AKT Signaling in Murine T-Cell Lymphoma.Skp2-dependent reactivation of AKT drives resistance to PI3K inhibitors.Immunological Approaches Towards Cancer and Inflammation: A Cross Talk.PI-103 attenuates PI3K-AKT signaling and induces apoptosis in murineT-cell lymphoma.
P2860
Q26781248-3935D2A2-DD05-4855-9603-02EEBFE97C63Q28073241-C1818437-1E30-4DBB-849B-4E9EBA5CE5B9Q28553400-2EE5897C-9D3D-40AD-AC90-49162E61ADA5Q29248893-73BB5BC0-F598-41FC-86CC-4E00C5AE1E5BQ33426930-CBFB9BE4-5550-41D7-8045-D3C73F82731DQ33853264-A53008CB-C210-4715-BA57-5D811E7252C3Q37288375-0675DA04-8031-4C71-AD5C-780445F20FBAQ37582671-70498BB7-CD77-406C-9D96-9208234AE955Q37695410-F65F0EA3-F794-49ED-819D-4493A070F184Q37696147-12817E1F-539E-45BB-9BEE-6BC55A5BB501Q37718224-6423D655-472D-4FF2-A2EF-A05CC8A7621CQ38543780-C0EB7190-51A2-4CA2-B5D4-3724059C1A68Q38684394-FE4ECA7C-C2CB-4948-94F4-D5A4D05FDF77Q38764654-53AF8E6F-1F50-4A43-8034-FB404EBAE155Q38785807-952DFBC9-9B17-42D3-B8F4-0DA4D9C9113FQ38792699-8BC0EF0D-66DC-4B54-A1F1-B35D612F3C60Q39168810-EE2D727A-36D1-4F89-9033-11096EE573FCQ39235281-01501D61-6878-4068-A862-EB36732655ADQ40447356-BC7B416E-223B-4443-A349-DCF07E306091Q40989800-5016E542-187A-40F1-B2AB-05293718E448Q42112265-6B553705-9433-45A2-9109-D1A8D8DC64BAQ46546002-13A3AA14-121D-4DC4-B2A0-564DFF770CE9Q47100175-8FDD56BE-9AF1-4B0A-A022-97B118252099Q47985197-7294B325-4FB0-4122-BDB6-071154AA4C9CQ48287837-C238765F-557A-4F24-A4F6-3ED87513B443Q51178862-06B191F2-8B02-4A48-ACCD-5176B68D7F6DQ52356988-85B61BD7-20AA-431E-BAFB-AA8DC4611556Q52584421-F274681E-D39B-455A-A759-BE4CC35F5B91Q54151779-994C268A-D321-4014-A910-0F152AA2D77F
P2860
The phosphoinositide 3-kinase pathway and therapy resistance in cancer
description
2015 nî lūn-bûn
@nan
2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
The phosphoinositide 3-kinase pathway and therapy resistance in cancer
@ast
The phosphoinositide 3-kinase pathway and therapy resistance in cancer
@en
The phosphoinositide 3-kinase pathway and therapy resistance in cancer
@nl
type
label
The phosphoinositide 3-kinase pathway and therapy resistance in cancer
@ast
The phosphoinositide 3-kinase pathway and therapy resistance in cancer
@en
The phosphoinositide 3-kinase pathway and therapy resistance in cancer
@nl
prefLabel
The phosphoinositide 3-kinase pathway and therapy resistance in cancer
@ast
The phosphoinositide 3-kinase pathway and therapy resistance in cancer
@en
The phosphoinositide 3-kinase pathway and therapy resistance in cancer
@nl
P2860
P3181
P356
P1433
P1476
The phosphoinositide 3-kinase pathway and therapy resistance in cancer
@en
P2093
Alex Toker
P2860
P3181
P356
10.12703/P7-13
P407
P577
2015-02-03T00:00:00Z